N6-甲基腺嘌呤与癌症的研究进展

doi:10.11904/j.issn.1002-3070.2019.04.013

Abstract

Abstract: N6-methyladenine(m⁶A),a major RNA methylation modification,affects the development and progression of human cancer through a variety of mechanisms.The m⁶A modification also affects multiple aspects of RNA metabolism,ranging from RNA processing,nuclear export,RNA translation to decay.In this review,the basic concepts of m⁶A methylation,regulation of m⁶A methyltransferase complex and m⁶A demethylases in several cancers and some m⁶A performed the biological function of the modification as m⁶A-binding proteins are introduced.In addition,the dual role of m⁶A methylation and its potential in clinical application are summarized in this review.

Key words: N6-methyladenine(m⁶A), Methyltransferases, Demethylases, Cancer, Epigenetics

CLC Number:

ZHANG Meiyin, LOU Ge. Advances progress of N6-methyladenine and cancer[J]. Journal of Practical Oncology, 2019, 33(4): 357-360.

References

1 Strahl BD,Allis CD.The language of covalent histone modifications[J].Nature,2000,403(6765):41-45.
2 Cantara WA,Crain PF,Rozenski J,et al.The RNA modification database,RNAMDB:2011 update[J].Nucleic Acids Res,2011,39:195-201.
3 Chen T,Hao YJ,Zhang Y,et al.m(6)A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency[J].Cell Stem Cell,2015,16(3):289-301.
4 Alarcón CR,Goodarzi H,Lee H,et al.HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events[J].Cell,2015,162(6):1299-1308.
5 Xiao W,Adhikari S,Dahal U,et al.Nuclear m(6)A reader YTHDC1 regulates mRNA splicing[J].Mol Cell,2016,61(4):507-519.
6 Dominissini D,Moshitch-Moshkovitz S,Schwartz S,et al.Topology of the human and mouse m(6)A RNA methylomes revealed by m(6)A-seq[J].Nature,2012,485:201-208.
7 Liu J,Yue Y,Han D,et al.A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J].Nat Chem Biol,2014,10(2):93-95.
8 Lin S,Choe J,Du P,et al.The m(6)A methyltransferase METTL3 promotes translation in human cancer cells[J].Mol Cell,2017,62(3):335-345.
9 Du M,Zhang Y,Mao Y,et al.MiR-33a sup-presses proliferation of NSCLC cells via tar-geting METTL3 mRNA[J].Biochem Biophys Res Commun,2017,482(4):582-589.
10 Cui Q,Shi H,Ye P,et al.m⁶A RNA methylation regulates the self re-newal and tumorigenesis of glioblastoma stem cells[J].Cell,2017,18(11):2622-2634.
11 Vu LP,Pickering BF,Cheng Y,et al.The N6-methyladenosine(m⁶A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells[J].Nat Med,2017,23(11):1369-1376.
12 Weng H,Huang H,Wu H,et al.METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m⁶A modification[J].Cell Stem Cell,2018,22(2):191-205.
13 Wang X,Li Z,Kong B,et al.Reduced m⁶A mRNA methylation is correlated with the progression of human cervical cancer[J].Oncotarget,2017,8(58):98918-98930.
14 Li X,Tang J,Huang W,et al.The m⁶A methyltransferase METTL3:acting as a tumor suppressor in renal cell carcinoma[J].Oncotarget,2017,8(56):96103-96116.
15 Zheng G,Dahl JA,Niu Y,et al.ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J].Mol Cell,2013,49(1):18-29.
16 Ma JZ,Yang F,Zhou CC,et al.METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methyladenosine-dependent primary microRNA processing[J].Hepatology,2017,65(2):529-543.
17 Wang J,Muntean AG,Hess JL.ECSASB2 mediates MLL degradation during hematopoietic differentiation[J].Blood,2012,119(5):1151-1161.
18 李毅鹏,张鑫宇,吕涵柠,等.MLLT6在白血病中的研究进展[J].实用肿瘤学杂志,2018,32(2):135-139.
19 Zhang S,Zhao BS,Zhou A,et al.m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program[J].Cancer Cell,2017,31(4):591-606.
20 Zhang C,Zhi WI,Lu H,et al.Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217-and ALKBH5-mediated modulation of RNA methylation in breast cancer cells[J].Oncotarget,2016,7(40):64527-64542.
21 Du H,Zhao Y,He J,et al.YTHDF2 destabilizes m⁶A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex[J].Nat Commun,2016,7:12626.
22 Shi H,Wang X,Lu Z,et al.YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA[J].Cell Res,2017,27(3):315.
23 Li A,Chen YS,Ping XL,et al.Cytoplasmic m⁶A reader YTHDF3 promotes mRNA translation[J].Cell Res,2017,27(3):444-447.
24 Patil DP,Chen CK,Pickering BF,et al.m⁶A RNA methylation promotes XIST-mediated transcriptional repression[J].Nature,2016,537(7620):369-373.
25 Xiao W,Adhikari S,Dahal U,et al.Nuclear m⁶A reader YTHDC1 regulates mRNA splicing[J].Mol Cell,2016,61(4):507-519.
26 Roost C,Lynch SR,Batista PJ,et al.Structure and thermodynamics of N6-methyladenosine in RNA:a spring-loaded base modification[J].J Am Chem Soc,2015,137(5):2107-2115.
27 Spitale RC,Flynn RA,Zhang QC,et al.Structural imprints in vivo decode RNA regulatory mechanisms[J].Nature,2015,519(7544):486-490.
28 Zhou KI,Parisien M,Dai Q,et al.N6-methyladenosine modification in a long noncoding RNA hairpin predisposes its conformation to protein binding[J].J Mol Biol,2016,428:822-833.
29 Liu N,Zhou KI,Parisien M,et al.N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein[J].Nucleic Acids Res,2017,45(10):6051-6063.
30 Xu C,Liu K,Ahmed H,et al.Structural basis for the discriminative recognition of N6-methyladenosine RNA by the human YT521-B homology domain family of proteins[J].J Biol Chem,2015,290(41):24902-24913.
31 Tanabe A,Tanikawa K,Tsunetomi M,et al.RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1a mRNA is translated[J].Cancer Lett,2016,376(1):34-42.
32 Nishizawa Y,Konno M,Asai A,et al.Oncogene c-Myc promotes epitranscriptome m⁶A reader YTHDF1 expression in colorectal cancer[J].Oncotarget,2018,9(7):7476-7486.

[1]	AN Weiwei, TANG Yali, ZHAO Lianhua, YANG Yue, WANG Xinling. Polyphenylene-polysaccharide complex from pinus koraiensis extract induces apoptosis in human breast cancer MCF-7 cells [J]. Journal of Practical Oncology, 2019, 33(4): 289-293.
[2]	SHEN Li, WEI Juncheng. Effect of miRNA-409-3p expression on proliferation of cervical cancer cells and chemotherapy sensitivity of cisplatin [J]. Journal of Practical Oncology, 2019, 33(4): 300-304.
[3]	ZHANG Beilei, LI Yi, WU Tao, JIANG Feng, ZHAO Hongxi, LI Yanhong. Mechanism study of sanguinarine inhibiting tumor growth of ovarian cancer by apoptosis induction [J]. Journal of Practical Oncology, 2019, 33(4): 305-309.
[4]	LI Jing, WU Huazhen, LIU Jisuo. A study on the mechanism of mi-362 targeting six1 inhibiting proliferation and migration of cervical cancer cells [J]. Journal of Practical Oncology, 2019, 33(4): 310-316.
[5]	LIU Jintao, GAO Ling, ZHOU Huiui. Expression of MAGEA4 and EB1 proteins in lung cancer tissues and their correlation with clinicopathological features and prognosis [J]. Journal of Practical Oncology, 2019, 33(4): 334-339.
[6]	HU Lin, SHEN Jia. Growth differentiation factor 15 plays a role in predicting and monitoring the cardiotoxicity of epirubicin/cyclophosphamide-docetaxel-trastuzumab in the treatment of patients with HER-2 positive breast cancer [J]. Journal of Practical Oncology, 2019, 33(4): 340-345.
[7]	PU Rui, ZHU Lin, XIA Tingting, BI Haoran, SUN Hongru, HUANG Hao, ZHANG Lei, ZHAO Yashuang. Relationship between the methylation status of CpG island in STAT1,STAT3 gene promoters in peripheral blood and prognosis of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(4): 346-351.
[8]	MA Yan, HE Hong, WANG Sainan. Clinical study of docetaxel in the treatment of metastatic breast cancer in different age groups [J]. Journal of Practical Oncology, 2019, 33(4): 352-356.
[9]	ZHAO Jinlu, LI Guodong, LIU Ming. Advanced in the relation between long-chain non-coding RNA CCAT1 and digestive system malignancies [J]. Journal of Practical Oncology, 2019, 33(4): 367-370.
[10]	YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors [J]. Journal of Practical Oncology, 2019, 33(4): 371-375.
[11]	FANG Xuan, CHEN Hongsheng, Li Guodong, LIU Ming. Advances in research on treatment of aberrant crypt foci [J]. Journal of Practical Oncology, 2019, 33(4): 376-379.
[12]	ZHU Shijia, XU Xiangying. Advance of whole brain radiotherapy irradiation of hippocampus in the treatment of small cell lung cancer [J]. Journal of Practical Oncology, 2019, 33(4): 380-383.
[13]	SUN Lichao,YANG Jing,SUN Lixin,ZHANG Yuan,YANG Zhihua,RAN Yuliang. Identification of monoclonal antibodies against hepatoma stem cells by screening for hepatoma spheroid cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 193-199.
[14]	ZHANG Jiawen,YU Yan,ZHANG Wei,CAO Jingyan,LUO Wen,SHANG Lihua. Serum metabolomics of small cell lung cancer patients based on UPLC-TOF/MS [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 200-205.
[15]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.

Advances progress of N6-methyladenine and cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments